285 related articles for article (PubMed ID: 20440589)
21. TRPV1 receptors in the CNS play a key role in broad-spectrum analgesia of TRPV1 antagonists.
Cui M; Honore P; Zhong C; Gauvin D; Mikusa J; Hernandez G; Chandran P; Gomtsyan A; Brown B; Bayburt EK; Marsh K; Bianchi B; McDonald H; Niforatos W; Neelands TR; Moreland RB; Decker MW; Lee CH; Sullivan JP; Faltynek CR
J Neurosci; 2006 Sep; 26(37):9385-93. PubMed ID: 16971522
[TBL] [Abstract][Full Text] [Related]
22. The pharmacological challenge to tame the transient receptor potential vanilloid-1 (TRPV1) nocisensor.
Holzer P
Br J Pharmacol; 2008 Dec; 155(8):1145-62. PubMed ID: 18806809
[TBL] [Abstract][Full Text] [Related]
23. Transient receptor potential vanilloid-1 antagonists: a survey of recent patent literature.
Voight EA; Kort ME
Expert Opin Ther Pat; 2010 Sep; 20(9):1107-22. PubMed ID: 20586701
[TBL] [Abstract][Full Text] [Related]
24. TRPV1-Targeted Drugs in Development for Human Pain Conditions.
Iftinca M; Defaye M; Altier C
Drugs; 2021 Jan; 81(1):7-27. PubMed ID: 33165872
[TBL] [Abstract][Full Text] [Related]
25. TRPV1 antagonists as a potential treatment for hyperalgesia.
Roberts LA; Connor M
Recent Pat CNS Drug Discov; 2006 Jan; 1(1):65-76. PubMed ID: 18221192
[TBL] [Abstract][Full Text] [Related]
26. Opioids and neuropathic pain.
Smith HS
Pain Physician; 2012 Jul; 15(3 Suppl):ES93-110. PubMed ID: 22786465
[TBL] [Abstract][Full Text] [Related]
27. Morphine inhibits acid-sensing ion channel currents in rat dorsal root ganglion neurons.
Cai Q; Qiu CY; Qiu F; Liu TT; Qu ZW; Liu YM; Hu WP
Brain Res; 2014 Mar; 1554():12-20. PubMed ID: 24491633
[TBL] [Abstract][Full Text] [Related]
28. Venom Peptide Toxins Targeting the Outer Pore Region of Transient Receptor Potential Vanilloid 1 in Pain: Implications for Analgesic Drug Development.
Hwang SM; Jo YY; Cohen CF; Kim YH; Berta T; Park CK
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628583
[TBL] [Abstract][Full Text] [Related]
29. Positive allosteric modulation of TRPV1 as a novel analgesic mechanism.
Lebovitz EE; Keller JM; Kominsky H; Kaszas K; Maric D; Iadarola MJ
Mol Pain; 2012 Sep; 8():70. PubMed ID: 22998799
[TBL] [Abstract][Full Text] [Related]
30. Ca(v)3.2 calcium channels: the key protagonist in the supraspinal effect of paracetamol.
Kerckhove N; Mallet C; François A; Boudes M; Chemin J; Voets T; Bourinet E; Alloui A; Eschalier A
Pain; 2014 Apr; 155(4):764-772. PubMed ID: 24447516
[TBL] [Abstract][Full Text] [Related]
31. Responsible prescribing of opioids for the management of chronic pain.
Nicholson B
Drugs; 2003; 63(1):17-32. PubMed ID: 12487620
[TBL] [Abstract][Full Text] [Related]
32. Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain.
Kinsey SG; Long JZ; O'Neal ST; Abdullah RA; Poklis JL; Boger DL; Cravatt BF; Lichtman AH
J Pharmacol Exp Ther; 2009 Sep; 330(3):902-10. PubMed ID: 19502530
[TBL] [Abstract][Full Text] [Related]
33. Fluorescence-Based Assay for TRPV1 Channels.
Moriello AS; De Petrocellis L; Vitale RM
Methods Mol Biol; 2023; 2576():119-131. PubMed ID: 36152181
[TBL] [Abstract][Full Text] [Related]
34. Analgesic transient receptor potential vanilloid-1-active compounds inhibit native and recombinant T-type calcium channels.
McArthur JR; Finol-Urdaneta RK; Adams DJ
Br J Pharmacol; 2019 Jul; 176(13):2264-2278. PubMed ID: 30927254
[TBL] [Abstract][Full Text] [Related]
35. Vanilloid receptor antagonists: emerging class of novel anti-inflammatory agents for pain management.
Pal M; Angaru S; Kodimuthali A; Dhingra N
Curr Pharm Des; 2009; 15(9):1008-26. PubMed ID: 19275664
[TBL] [Abstract][Full Text] [Related]
36. Piperazinyl carbamate fatty acid amide hydrolase inhibitors and transient receptor potential channel modulators as "dual-target" analgesics.
Maione S; Costa B; Piscitelli F; Morera E; De Chiaro M; Comelli F; Boccella S; Guida F; Verde R; Ortar G; Di Marzo V
Pharmacol Res; 2013 Oct; 76():98-105. PubMed ID: 23911581
[TBL] [Abstract][Full Text] [Related]
37. Modulation of TRPV1 channel function by natural products in the treatment of pain.
Abbas MA
Chem Biol Interact; 2020 Oct; 330():109178. PubMed ID: 32738201
[TBL] [Abstract][Full Text] [Related]
38. Clinical development of TRPV1 antagonists: targeting a pivotal point in the pain pathway.
Gunthorpe MJ; Chizh BA
Drug Discov Today; 2009 Jan; 14(1-2):56-67. PubMed ID: 19063991
[TBL] [Abstract][Full Text] [Related]
39. The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept.
Szallasi A; Cortright DN; Blum CA; Eid SR
Nat Rev Drug Discov; 2007 May; 6(5):357-72. PubMed ID: 17464295
[TBL] [Abstract][Full Text] [Related]
40. Removing TRPV1-expressing primary afferent neurons potentiates the spinal analgesic effect of delta-opioid agonists on mechano-nociception.
Chen SR; Pan HL
Neuropharmacology; 2008 Aug; 55(2):215-22. PubMed ID: 18579164
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
